Imagine a way to fix sagging pelvic organs without needing a major operation. Instead of waiting for the condition to get severe enough for surgery, this device acts like a gentle internal repair tool. It allows women to recover quickly and get back to their normal lives without the pain or long downtime of a hospital stay.
Women with early-stage pelvic organ prolapse have no repair options until the condition worsens enough for invasive surgery. Current surgeries involve long recovery times, pain, and risks of relapse.
The Mendit (formerly Apyx) device, an incision-free, minimally invasive tool for pelvic floor repair that can be used in a doctor's office under local anesthesia.
If you are a distributor dealing with a lack of non-surgical options for pelvic floor disorders — this project developed the Mendit device that provides an incision-free repair method. It targets the 89% of cases seeking treatment for early stage prolapse. This allows for a new product line that doesn't require hospital infrastructure.
If you are a clinic owner dealing with high surgical referral rates and long patient recovery times — this project developed a tool that can be used under local anesthesia in the doctor's office. It replaces the need for surgery for 10% of patients at advanced stages. This increases patient throughput and reduces recovery time.
If you are a health administrator dealing with high costs of surgical interventions and limited surgical capacity — this project developed a cost-effective, minimally invasive repair solution. It addresses a condition affecting nearly 50% of women over 40 globally. This reduces the burden on operating theaters.
Based on available project data, the Mendit device is described as cost-effective compared to traditional surgical options.
Yes, the project targets both developed and underserved communities where surgical options are limited, aiming to treat thousands of women by 2030.
The company has secured robust IP protection, including an allowed European patent that supports its commercial expansion.
The device is already FDA cleared, and CE marks are on track for Q1 2026.
The company has secured financial runway until 2027 and is targeting impact goals for 2025-2030.
The project is led by a single SME, Escala Medical Ltd from Israel. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercialization and regulatory clearance rather than basic research.
Contact Escala Medical Ltd regarding the Mendit device
Contact us to explore distribution partnerships for the Mendit device in the EU.
